Quest Diagnostics (DGX) Common Equity (2009 - 2026)

Quest Diagnostics has disclosed Common Equity across 18 years of filings, most recently posting $7.4 billion for Q1 2026.

• Common Equity for Q1 2026 came in at $7.4 billion, up 5.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.4 billion (up 5.8% YoY), and the FY2025 annual result was $7.2 billion, up 5.24% from the prior year.
• Common Equity came in at $7.4 billion for Q1 2026 at Quest Diagnostics, up from $7.2 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $7.4 billion in Q1 2026 to a low of $5.9 billion in Q4 2022.
• The 5-year median for Common Equity is $6.5 billion (2024), against an average of $6.6 billion.
• Across the five-year window, Common Equity fell 8.53% in 2022 and climbed 9.15% in 2025, its largest moves.
• Quest Diagnostics' Common Equity stood at $5.9 billion in 2022, then grew by 6.95% to $6.3 billion in 2023, then gained by 7.43% to $6.8 billion in 2024, then gained by 5.24% to $7.2 billion in 2025, then increased by 2.73% to $7.4 billion in 2026.
• The last three Common Equity figures came in at $7.4 billion (Q1 2026), $7.2 billion (Q4 2025), and $7.3 billion (Q3 2025), per Business Quant data.